<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00695370</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0035</org_study_id>
    <nct_id>NCT00695370</nct_id>
  </id_info>
  <brief_title>Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children</brief_title>
  <official_title>Hematopoietic Progenitor Cell Mobilization in Children With Malignancies: Evaluation of Pegfilgrastim at 300µg/kg in Hematological Steady State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      Hypothesis: pegfilgrastim at 300 µg/kg in hematological steady state provides an efficient
      stem cell mobilization in children with malignancies

      Design: phase 2 study.

      Judgment criterion: percentage of children achieving at least 5x10e6 CD34 cells with a
      standard apheresis (less than 2 blood volume processed)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients: consecutively referred for HSC mobilization. At least 17 days after the previous
      chemotherapy. No hematological growth factor during the 8 previous days.

      Mobilization: one sc injection of 300 µg/kg pegfilgrastim (Neulasta, Amgen)

      Evaluation during the study: CD34 circulating cells from day 2 to day 7 ; AE recording

      Judgment criterion: percentage of children achieving at least 5x10e6 CD34 cells with a
      standard apheresis (less than 2 blood volume processed)

      Analysis: sequential Bayesian study
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruiting or enrolling participants has halted and will not resume
  </why_stopped>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">January 2008</completion_date>
  <primary_completion_date type="Anticipated">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of children achieving at least 5x10e6 CD34 cells with a standard apheresis (less than 2 blood volume processed)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects Number of apheresis required to achieved a graft of at least 5x10e6 CD34 cells</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Solid Malignancies</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegfilgrastim (drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  0 to 18 years

          -  solid malignancy

          -  Lansky score &gt;70%

          -  more than 17 days since the beginning of the last chemotherapy cycle

          -  absolute neutrophil count (ANC) greater than 1×109/l

          -  no administration of any hematopoietic growth factor in the previous 8 days

        Exclusion Criteria:

          -  clinical or biological conditions precluding the mobilization or collection procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Etienne Merlin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2008</study_first_submitted>
  <study_first_submitted_qc>June 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2008</study_first_posted>
  <last_update_submitted>June 12, 2008</last_update_submitted>
  <last_update_submitted_qc>June 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr Etienne MERLIN</name_title>
    <organization>CHU Clermont-Ferrand</organization>
  </responsible_party>
  <keyword>Children</keyword>
  <keyword>cancer</keyword>
  <keyword>Bone marrow transplantation</keyword>
  <keyword>Mobilization</keyword>
  <keyword>G-CSF</keyword>
  <keyword>Children with solid malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

